Form 4: Arcutis EVP Sells Shares for Tax Obligations

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 1,697 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported the sale of common stock.
• The transactions occurred on December 31, 2025.
• A total of 1,697 shares were sold across two separate transactions.
• 541 shares were sold at a weighted average price of $28.81 per share, with individual sale prices ranging from $28.08 to $29.08.
• An additional 1,156 shares were sold at a weighted average price of $29.3893 per share, with individual sale prices ranging from $29.0829 to $29.57.
• The sales were executed solely to cover tax withholding obligations associated with the vesting of performance-based Restricted Stock Units, which were granted on August 3, 2020.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Following these reported transactions, Patrick Burnett beneficially owns 96,610 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is neutral as it's a non-discretionary sale for tax purposes, a common occurrence for executives with equity compensation. It neither signals strong confidence nor a lack thereof in the company's future.

Positives

• The sale was non-discretionary, explicitly stated to cover tax withholding obligations, which is a common and expected event for executives receiving equity compensation and does not signal a lack of confidence in the company.
• The transaction was executed under a Rule 10b5-1(c) plan, demonstrating pre-planning and adherence to insider trading regulations.

Negatives

• A minor reduction in direct insider ownership, even for tax purposes, slightly decreases the alignment of interests between the executive and shareholders.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general implication of insider share sales, which in this case is mitigated by the stated tax-related purpose.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to a past insider transaction.

Management Comments

• "The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020."

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is a common occurrence across all industries, including the biotechnology sector. It does not provide specific insights into broader industry trends, competitive positioning, or the operational performance of Arcutis Biotherapeutics.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider stock sale for tax purposes, a common practice for executives in publicly traded companies across various sectors, including biotechnology.
• The execution of the sale under a Rule 10b5-1 plan is a standard and recommended practice for insiders to manage equity compensation while complying with insider trading regulations, aligning with best practices in corporate governance.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature for tax purposes mitigates concerns about management's confidence in the company.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported insider sale by Patrick Burnett is explicitly for tax withholding obligations related to vested restricted stock units and was conducted under a Rule 10b5-1 plan. This is a routine, non-discretionary transaction and does not reflect a change in the executive's view of the company's prospects. Therefore, it provides no new fundamental information to alter an investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Stock Sale, Patrick Burnett, Restricted Stock Units, Tax Withholding, Biotechnology, Pharmaceuticals